27 TWENTYFOURSEVENBIOPHARMA Issue 2 / June 2025 What new products or innovations is your company showcasing at BIO 2025 this year? Mabion is proudly showcasing its end‑to‑end mammalian cell‑based CDMO platform, with a strong emphasis on the development and manufacturing of biologics. In addition to the capabilities, we want to point that Mabion is a Champion in the International Biologics CDMO Leadership Awards 2025 competition. We are also planning to announce some business surprise during our Tuesday party from 5 PM. We encourage you to visit our website for more information on this topic. What are you hoping to achieve from the event? At BIO International Convention 2025, Mabion aims to strengthen its role as a global strategic partner for biopharma companies advancing complex biologic programs. Our primary goal is to build new relationships with innovative biotech firms seeking a reliable, flexible, and scientifically driven CDMO for monoclonal and bispecific antibody development. We are also focused on deepening connections with existing partners and collaborators by sharing updates on our capabilities, recent project successes, and future directions. Through one-on-one meetings and technical discussions at our booth, we hope to identify opportunities for joint development, clinical supply agreements, and technology transfer projects. How does your company stay ahead of industry trends and developments in the pharmaceutical sector? Mabion actively monitor emerging developments in biopharmaceuticals. Our teams are embedded in global regulatory and scientific networks, allowing us to anticipate changes such as updates to GMP Annex 1, FDA and EMA expectations for biologics, and the impact of digitalization across quality and manufacturing systems. We also maintain close relationships with technology providers like Sartorius, Cytiva, and Steriline, ensuring early access to platform innovations in upstream, downstream, and fill-finish operations. What challenges are you currently facing in the pharmaceutical market, and how is your organization addressing them? One of the most significant challenges Mabion faces in the biopharma market is the growing complexity and pace of biologics development. Sponsors increasingly expect CDMOs to deliver both scientific depth and rapid execution, while adapting to shifting regulatory expectations across multiple jurisdictions. This is especially true for biologics like monoclonal and bispecific antibodies, which require advanced manufacturing capabilities, robust analytics, and precise quality oversight. In parallel, cost pressures and global supply chain uncertainties are pushing companies to seek regional partners who can deliver both flexibility and GMP compliance. To address these challenges, Mabion has invested in a fully integrated, single-site CDMO platform focused on mammalian cell-based production. This model allows us to reduce handovers, minimize risk, and shorten timelines by providing drug substance manufacturing, fill-finish, and clinical packaging all under one roof. We’ve also expanded our analytical capabilities to support deep product characterization, method validation, and release testing aligned with EMA and FDA expectations. MARTY HENEHAN Vice President of Business Development Mabion BIO INTERNATIONAL CONVENTION
RkJQdWJsaXNoZXIy MjY2OTA4MA==